M. Flint Beal, MD, University of Virginia 1976 - Publications

Affiliations: 
Neurology Cornell University, Ithaca, NY, United States 
Area:
http://www.researchprofiles.collexis.com/jad/expert.asp?u_id=41
Website:
http://www.med.cornell.edu/research/mfbeal/publications.html

449 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nature Reviews. Drug Discovery. PMID 32709961 DOI: 10.1038/S41573-020-0072-X  0.336
2020 Fourcade S, Goicoechea L, Parameswaran J, Schlüter A, Launay N, Ruiz M, Seyer A, Colsch B, Calingasan NY, Ferrer I, Beal MF, Sedel F, Pujol A. High-dose biotin restores redox balance, energy and lipid homeostasis, and axonal health in a model of adrenoleukodystrophy. Brain Pathology (Zurich, Switzerland). PMID 32511826 DOI: 10.1111/Bpa.12869  0.313
2020 Cristóvão AC, Campos FL, Je G, Esteves M, Guhathakurta S, Yang L, Beal MF, Fonseca BM, Salgado AJ, Queiroz J, Sousa N, Bernardino L, Alves G, Yoon KS, Kim YS. Characterization of a Parkinson's disease rat model using an upgraded paraquat exposure paradigm. The European Journal of Neuroscience. PMID 31958881 DOI: 10.1111/Ejn.14683  0.664
2019 Lloret A, Beal MF. PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All. Neurochemical Research. PMID 31065944 DOI: 10.1007/S11064-019-02809-1  0.379
2019 Shchepinov MS, Beal MF, Brenna JT, Calingasan NY, Chiluwal J, Korneenko TV, Lee M, Liu L, Milne GL, Pestov NB, Tapias V, Vijg J. Beneficial Effect of Deuterated Polyunsaturated Fatty Acids in Rodent Models of Parkinson's Disease and Aging European Journal of Lipid Science and Technology. 1800469. DOI: 10.1002/Ejlt.201800469  0.331
2018 Bose A, Beal MF. Mitochondrial dysfunction and oxidative stress in induced pluripotent stem cell models of Parkinson's disease. The European Journal of Neuroscience. PMID 30408242 DOI: 10.1111/Ejn.14264  0.395
2018 Ranea-Robles P, Launay N, Ruiz M, Calingasan NY, Dumont M, Naudí A, Portero-Otín M, Pamplona R, Ferrer I, Beal MF, Fourcade S, Pujol A. Aberrant regulation of the GSK-3β/NRF2 axis unveils a novel therapy for adrenoleukodystrophy. Embo Molecular Medicine. PMID 29997171 DOI: 10.15252/Emmm.201708604  0.542
2018 Tapias V, Jainuddin S, Ahuja M, Stack C, Elipenahli C, Vignisse J, Gerges M, Starkova N, Xu H, Starkov AA, Bettendorff L, Hushpulian DM, Smirnova NA, Gazaryan IG, Kaidery NA, ... ... Beal MF, et al. Benfotiamine Treatment Activates the Nrf2/ARE Pathway and is Neuroprotective in a Transgenic Mouse Model of Tauopathy. Human Molecular Genetics. PMID 29860433 DOI: 10.1093/Hmg/Ddy201  0.643
2018 Chen Q, Kirk K, Shurubor YI, Zhao D, Arreguin AJ, Shahi I, Valsecchi F, Primiano G, Calder EL, Carelli V, Denton TT, Beal MF, Gross SS, Manfredi G, D'Aurelio M. Rewiring of Glutamine Metabolism Is a Bioenergetic Adaptation of Human Cells with Mitochondrial DNA Mutations. Cell Metabolism. PMID 29657030 DOI: 10.1016/J.Cmet.2018.03.002  0.359
2016 Chen H, Denton TT, Xu H, Calingasan N, Beal MF, Gibson GE. Reductions in the mitochondrial enzyme α-ketoglutarate dehydrogenase complex in neurodegenerative disease - beneficial or detrimental? Journal of Neurochemistry. PMID 27580471 DOI: 10.1111/Jnc.13836  0.381
2016 Bose A, Beal MF. Mitochondrial dysfunction in Parkinson's disease. Journal of Neurochemistry. PMID 27546335 DOI: 10.1111/Jnc.13731  0.373
2016 Ahuja M, Ammal Kaidery N, Yang L, Calingasan N, Smirnova N, Gaisin A, Gaisina IN, Gazaryan I, Hushpulian DM, Kaddour-Djebbar I, Bollag WB, Morgan JC, Ratan RR, Starkov AA, Beal MF, et al. Distinct Nrf2 Signaling Mechanisms of Fumaric Acid Esters and Their Role in Neuroprotection against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Experimental Parkinson's-Like Disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 36: 6332-51. PMID 27277809 DOI: 10.1523/Jneurosci.0426-16.2016  0.723
2016 Chandra A, Sharma A, Calingasan NY, White JM, Shurubor Y, Yang XW, Beal MF, Johri A. Enhanced Mitochondrial Biogenesis Ameliorates Disease Phenotype in a Full-Length Mouse Model of Huntington's Disease. Human Molecular Genetics. PMID 27008868 DOI: 10.1093/Hmg/Ddw095  0.622
2015 Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, DeLoach A, Calingasan NY, Beal MF, Kiaei M. Preferential PPAR-alpha activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Human Molecular Genetics. PMID 26604138 DOI: 10.1093/Hmg/Ddv477  0.416
2015 Clark-Matott J, Saleem A, Dai Y, Shurubor Y, Ma X, Safdar A, Beal MF, Tarnopolsky M, Simon DK. Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain. Neurobiology of Aging. 36: 2972-83. PMID 26294258 DOI: 10.1016/J.Neurobiolaging.2015.07.020  0.473
2015 Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging. 25: 105-10. PMID 24325203 DOI: 10.1111/Jon.12074  0.334
2014 Boussicault L, Hérard AS, Calingasan N, Petit F, Malgorn C, Merienne N, Jan C, Gaillard MC, Lerchundi R, Barros LF, Escartin C, Delzescaux T, Mariani J, Hantraye P, Beal MF, et al. Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 34: 1500-10. PMID 24938402 DOI: 10.1038/Jcbfm.2014.110  0.628
2014 Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. Jama Neurology. 71: 543-52. PMID 24664227 DOI: 10.1001/Jamaneurol.2014.131  0.486
2014 Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C. Sex differences in cerebral energy metabolism in Parkinson's disease: a phosphorus magnetic resonance spectroscopic imaging study. Parkinsonism & Related Disorders. 20: 545-8. PMID 24593902 DOI: 10.1016/J.Parkreldis.2014.02.003  0.31
2014 Chandra A, Johri A, Beal MF. Prospects for neuroprotective therapies in prodromal Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 285-93. PMID 24573776 DOI: 10.1002/Mds.25835  0.59
2014 Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jové M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Human Molecular Genetics. 23: 3716-32. PMID 24556215 DOI: 10.1093/Hmg/Ddu080  0.665
2014 Dumont M, Stack C, Elipenahli C, Jainuddin S, Launay N, Gerges M, Starkova N, Starkov AA, Calingasan NY, Tampellini D, Pujol A, Beal MF. PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 1745-55. PMID 24398293 DOI: 10.1096/Fj.13-236331  0.594
2013 Inoue K, Rispoli J, Yang L, Macleod D, Beal MF, Klann E, Abeliovich A. Coordinate regulation of mature dopaminergic axon morphology by macroautophagy and the PTEN signaling pathway. Plos Genetics. 9: e1003845. PMID 24098148 DOI: 10.1371/Journal.Pgen.1003845  0.582
2013 Morató L, Galino J, Ruiz M, Calingasan NY, Starkov AA, Dumont M, Naudí A, Martínez JJ, Aubourg P, Portero-Otín M, Pamplona R, Galea E, Beal MF, Ferrer I, Fourcade S, et al. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain : a Journal of Neurology. 136: 2432-43. PMID 23794606 DOI: 10.1093/Brain/Awt143  0.556
2013 Damiano M, Diguet E, Malgorn C, D'Aurelio M, Galvan L, Petit F, Benhaim L, Guillermier M, Houitte D, Dufour N, Hantraye P, Canals JM, Alberch J, Delzescaux T, Déglon N, ... Beal MF, et al. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Human Molecular Genetics. 22: 3869-82. PMID 23720495 DOI: 10.1093/Hmg/Ddt242  0.743
2013 Johri A, Chandra A, Beal MF. PGC-1α, mitochondrial dysfunction, and Huntington's disease. Free Radical Biology & Medicine. 62: 37-46. PMID 23602910 DOI: 10.1016/J.Freeradbiomed.2013.04.016  0.591
2013 Franco MC, Ye Y, Refakis CA, Feldman JL, Stokes AL, Basso M, Melero Fernández de Mera RM, Sparrow NA, Calingasan NY, Kiaei M, Rhoads TW, Ma TC, Grumet M, Barnes S, Beal MF, et al. Nitration of Hsp90 induces cell death. Proceedings of the National Academy of Sciences of the United States of America. 110: E1102-11. PMID 23487751 DOI: 10.1073/Pnas.1215177110  0.342
2013 Kiss G, Konrad C, Doczi J, Starkov AA, Kawamata H, Manfredi G, Zhang SF, Gibson GE, Beal MF, Adam-Vizi V, Chinopoulos C. The negative impact of α-ketoglutarate dehydrogenase complex deficiency on matrix substrate-level phosphorylation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 27: 2392-406. PMID 23475850 DOI: 10.1096/Fj.12-220202  0.356
2013 Chaturvedi RK, Beal MF. Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases. Molecular and Cellular Neurosciences. 55: 101-14. PMID 23220289 DOI: 10.1016/J.Mcn.2012.11.011  0.558
2013 Kaidery NA, Banerjee R, Yang L, Smirnova NA, Hushpulian DM, Liby KT, Williams CR, Yamamoto M, Kensler TW, Ratan RR, Sporn MB, Beal MF, Gazaryan IG, Thomas B. Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxidants & Redox Signaling. 18: 139-57. PMID 22746536 DOI: 10.1089/Ars.2011.4491  0.707
2012 Yao J, Ho D, Calingasan NY, Pipalia NH, Lin MT, Beal MF. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. The Journal of Experimental Medicine. 209: 2501-13. PMID 23209315 DOI: 10.1084/Jem.20121239  0.562
2012 Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingasan NY, Yang L, Tampellini D, Starkov AA, Chan RB, Di Paolo G, Pujol A, Beal MF. Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice. Human Molecular Genetics. 21: 5091-105. PMID 22922230 DOI: 10.1093/Hmg/Dds355  0.712
2012 Lin MT, Cantuti-Castelvetri I, Zheng K, Jackson KE, Tan YB, Arzberger T, Lees AJ, Betensky RA, Beal MF, Simon DK. Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Annals of Neurology. 71: 850-4. PMID 22718549 DOI: 10.1002/Ana.23568  0.627
2012 Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. The Journal of Pharmacology and Experimental Therapeutics. 342: 619-30. PMID 22700435 DOI: 10.1124/Jpet.112.192138  0.616
2012 Chaturvedi RK, Hennessey T, Johri A, Tiwari SK, Mishra D, Agarwal S, Kim YS, Beal MF. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease. Human Molecular Genetics. 21: 3474-88. PMID 22589249 DOI: 10.1093/Hmg/Dds178  0.714
2012 Gollamudi S, Johri A, Calingasan NY, Yang L, Elemento O, Beal MF. Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease. Plos One. 7: e36191. PMID 22563483 DOI: 10.1371/Journal.Pone.0036191  0.679
2012 Johri A, Beal MF. Muscling in on PGC-1α for improved quality of life in ALS. Cell Metabolism. 15: 567-9. PMID 22560208 DOI: 10.1016/J.Cmet.2012.04.015  0.524
2012 Islam R, Yang L, Sah M, Kannan K, Anamani D, Vijayan C, Kwok J, Cantino ME, Beal MF, Fridell YW. A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson's disease model. Neurobiology of Disease. 46: 137-46. PMID 22266335 DOI: 10.1016/J.Nbd.2011.12.055  0.662
2012 Johri A, Beal MF. Antioxidants in Huntington's disease. Biochimica Et Biophysica Acta. 1822: 664-74. PMID 22138129 DOI: 10.1016/J.Bbadis.2011.11.014  0.634
2012 Choi DH, Cristóvão AC, Guhathakurta S, Lee J, Joh TH, Beal MF, Kim YS. NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxidants & Redox Signaling. 16: 1033-45. PMID 22098189 DOI: 10.1089/Ars.2011.3960  0.512
2012 Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, Chandra A, Beal MF. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Human Molecular Genetics. 21: 1124-37. PMID 22095692 DOI: 10.1093/Hmg/Ddr541  0.747
2012 Elipenahli C, Stack C, Jainuddin S, Gerges M, Yang L, Starkov A, Beal MF, Dumont M. Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice. Journal of Alzheimer's Disease : Jad. 28: 173-82. PMID 21971408 DOI: 10.3233/Jad-2011-111190  0.704
2012 Thomas B, Banerjee R, Starkova NN, Zhang SF, Calingasan NY, Yang L, Wille E, Lorenzo BJ, Ho DJ, Beal MF, Starkov A. Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease. Antioxidants & Redox Signaling. 16: 855-68. PMID 21529244 DOI: 10.1089/Ars.2010.3849  0.734
2012 Lin MT, Cantuti-Castelvetri I, Lees AJ, Beal MF, Simon DK. Reply Annals of Neurology. 72: 823-824. DOI: 10.1002/ana.23739  0.308
2011 Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C, Buch A, Yang L, Beal MF, Surmeier DJ, Kordower JH, Tabar V, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 480: 547-51. PMID 22056989 DOI: 10.1038/Nature10648  0.637
2011 Henchcliffe C, Dodel R, Beal MF. Biomarkers of Parkinson's disease and Dementia with Lewy bodies. Progress in Neurobiology. 95: 601-13. PMID 21983334 DOI: 10.1016/J.Pneurobio.2011.09.002  0.315
2011 Yang L, Beal MF. Determination of neurotransmitter levels in models of Parkinson's disease by HPLC-ECD. Methods in Molecular Biology (Clifton, N.J.). 793: 401-15. PMID 21913116 DOI: 10.1007/978-1-61779-328-8_27  0.612
2011 Dumont M, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF. Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 27: 211-23. PMID 21799249 DOI: 10.3233/Jad-2011-110209  0.817
2011 Johri A, Starkov AA, Chandra A, Hennessey T, Sharma A, Orobello S, Squitieri F, Yang L, Beal MF. Truncated peroxisome proliferator-activated receptor-γ coactivator 1α splice variant is severely altered in Huntington's disease. Neuro-Degenerative Diseases. 8: 496-503. PMID 21757867 DOI: 10.1159/000327910  0.719
2011 Thomas B, Beal MF. Molecular insights into Parkinson's disease. F1000 Medicine Reports. 3: 7. PMID 21655332 DOI: 10.3410/M3-7  0.546
2011 Ramonet D, Daher JP, Lin BM, Stafa K, Kim J, Banerjee R, Westerlund M, Pletnikova O, Glauser L, Yang L, Liu Y, Swing DA, Beal MF, Troncoso JC, McCaffery JM, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. Plos One. 6: e18568. PMID 21494637 DOI: 10.1371/Journal.Pone.0018568  0.712
2011 Neymotin A, Calingasan NY, Wille E, Naseri N, Petri S, Damiano M, Liby KT, Risingsong R, Sporn M, Beal MF, Kiaei M. Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology & Medicine. 51: 88-96. PMID 21457778 DOI: 10.1016/J.Freeradbiomed.2011.03.027  0.726
2011 Beal MF. Neuroprotective effects of creatine. Amino Acids. 40: 1305-13. PMID 21448659 DOI: 10.1007/S00726-011-0851-0  0.463
2011 Johri A, Chaturvedi RK, Beal MF. Hugging tight in Huntington's. Nature Medicine. 17: 245-6. PMID 21383715 DOI: 10.1038/Nm0311-245  0.677
2011 Choi DH, Kim YJ, Kim YG, Joh TH, Beal MF, Kim YS. Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. The Journal of Biological Chemistry. 286: 14168-77. PMID 21330369 DOI: 10.1074/Jbc.M111.222430  0.425
2011 Dumont M, Stack C, Elipenhali C, Calingasan NY, Wille E, Beal MF. Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's disease. Neuroscience Letters. 492: 150-4. PMID 21300136 DOI: 10.1016/J.Neulet.2011.01.077  0.566
2011 Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radical Biology & Medicine. 51: 1014-26. PMID 21130159 DOI: 10.1016/J.Freeradbiomed.2010.11.026  0.559
2011 Zhang SF, Hennessey T, Yang L, Starkova NN, Beal MF, Starkov AA. Impaired brain creatine kinase activity in Huntington's disease. Neuro-Degenerative Diseases. 8: 194-201. PMID 21124007 DOI: 10.1159/000321681  0.594
2011 Choi DH, Hwang O, Lee KH, Lee J, Beal MF, Kim YS. DJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell death. Antioxidants & Redox Signaling. 14: 2137-50. PMID 20969476 DOI: 10.1089/Ars.2009.3059  0.479
2011 Godau J, Lindig T, Schöls L, Berg D, Synofzik M, Frederiksen KS, Garde E, Skimminge A, Ryberg C, Rostrup E, Baaré WFC, Siebner HR, Hejl A, Leffers A, Fiedorowicz JG, ... ... Beal MF, et al. Contents Vol. 8, 2011 Neurodegenerative Diseases. 8. DOI: 10.1159/000330927  0.637
2011 Johri A, Chaturvedi RK, Beal MF. Erratum: Corrigendum: Hugging tight in Huntington's Nature Medicine. 17: 514-514. DOI: 10.1038/Nm0411-514C  0.613
2011 Johri A, Chaturvedi RK, Beal MF. Erratum: Hugging tight in Huntington's Nature Medicine. 17: 514-514. DOI: 10.1038/Nm0411-514B  0.582
2010 Yao J, Hennessey T, Flynt A, Lai E, Beal MF, Lin MT. MicroRNA-related cofilin abnormality in Alzheimer's disease. Plos One. 5: e15546. PMID 21179570 DOI: 10.1371/Journal.Pone.0015546  0.561
2010 Banerjee R, Beal MF, Thomas B. Autophagy in neurodegenerative disorders: pathogenic roles and therapeutic implications. Trends in Neurosciences. 33: 541-9. PMID 20947179 DOI: 10.1016/J.Tins.2010.09.001  0.541
2010 Beal MF. Parkinson's disease: a model dilemma. Nature. 466: S8-10. PMID 20739935 DOI: 10.1038/466S8A  0.335
2010 Johri A, Beal MF. Hunting-ton for new proteases: MMPs as the new target? Neuron. 67: 171-3. PMID 20670824 DOI: 10.1016/J.Neuron.2010.07.011  0.557
2010 Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, ... ... Beal MF, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1924-8. PMID 20669312 DOI: 10.1002/mds.22408  0.394
2010 Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas B, Ding A. Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 4639-47. PMID 20667979 DOI: 10.1096/fj.10.161471  0.7
2010 McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. Embo Molecular Medicine. 2: 349-70. PMID 20665636 DOI: 10.1002/Emmm.201000084  0.563
2010 Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Human Molecular Genetics. 19: 3919-35. PMID 20660112 DOI: 10.1093/Hmg/Ddq306  0.382
2010 Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Experimental Neurology. 225: 74-84. PMID 20561979 DOI: 10.1016/J.Expneurol.2010.05.006  0.556
2010 Chaturvedi RK, Calingasan NY, Yang L, Hennessey T, Johri A, Beal MF. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Human Molecular Genetics. 19: 3190-205. PMID 20529956 DOI: 10.1093/Hmg/Ddq229  0.767
2010 Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 20: S633-43. PMID 20421689 DOI: 10.3233/Jad-2010-100507  0.653
2010 Stack C, Ho D, Wille E, Calingasan NY, Williams C, Liby K, Sporn M, Dumont M, Beal MF. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radical Biology & Medicine. 49: 147-58. PMID 20338236 DOI: 10.1016/J.Freeradbiomed.2010.03.017  0.586
2010 Thomas B, Beal MF. Mitochondrial therapies for Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: S155-60. PMID 20187246 DOI: 10.1002/Mds.22781  0.546
2010 Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C, Beal MF, Nathan C, Ding A. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. The Journal of Experimental Medicine. 207: 117-28. PMID 20026663 DOI: 10.1084/Jem.20091568  0.538
2010 Cleren C, Calingasan NY, Starkov A, Jacquard C, Chen J, Brouillet E, Beal MF. Promethazine protects against 3-nitropropionic acid-induced neurotoxicity. Neurochemistry International. 56: 208-12. PMID 19852992 DOI: 10.1016/J.Neuint.2009.10.006  0.623
2010 Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochimica Et Biophysica Acta. 1802: 122-34. PMID 19715758 DOI: 10.1016/J.Bbadis.2009.08.010  0.399
2010 Zhu X, Beal MF, Wang X, Perry G, Smith MA. Preface: Mitochondria and neurodegenerative diseases Journal of Alzheimer's Disease. 20: S253. DOI: 10.3233/Jad-2010-1424  0.543
2009 Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism & Related Disorders. 15: S189-94. PMID 20082988 DOI: 10.1016/S1353-8020(09)70812-0  0.402
2009 Andres-Mateos E, Mejias R, Sasaki M, Li X, Lin BM, Biskup S, Zhang L, Banerjee R, Thomas B, Yang L, Liu G, Beal MF, Huso DL, Dawson TM, Dawson VL. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine). The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 15846-50. PMID 20016100 DOI: 10.1523/Jneurosci.4357-09.2009  0.711
2009 Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatric Disease and Treatment. 5: 597-610. PMID 19966907 DOI: 10.2147/Ndt.S5212  0.407
2009 Neymotin A, Petri S, Calingasan NY, Wille E, Schafer P, Stewart C, Hensley K, Beal MF, Kiaei M. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Experimental Neurology. 220: 191-7. PMID 19733563 DOI: 10.1016/J.Expneurol.2009.08.028  0.561
2009 Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease. Bmc Neuroscience. 10: 109. PMID 19723328 DOI: 10.1186/1471-2202-10-109  0.638
2009 Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, Andersen JK. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. The Journal of Biological Chemistry. 284: 29065-76. PMID 19679656 DOI: 10.1074/Jbc.M109.000638  0.637
2009 Yang L, Shi Q, Ho DJ, Starkov AA, Wille EJ, Xu H, Chen HL, Zhang S, Stack CM, Calingasan NY, Gibson GE, Beal MF. Mice deficient in dihydrolipoyl succinyl transferase show increased vulnerability to mitochondrial toxins. Neurobiology of Disease. 36: 320-30. PMID 19660549 DOI: 10.1016/J.Nbd.2009.07.023  0.681
2009 Dumont M, Ho DJ, Calingasan NY, Xu H, Gibson G, Beal MF. Mitochondrial dihydrolipoyl succinyltransferase deficiency accelerates amyloid pathology and memory deficit in a transgenic mouse model of amyloid deposition. Free Radical Biology & Medicine. 47: 1019-27. PMID 19596066 DOI: 10.1016/J.Freeradbiomed.2009.07.008  0.565
2009 Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, Beal MF, Burke RE, Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nature Neuroscience. 12: 826-8. PMID 19503083 DOI: 10.1038/Nn.2349  0.403
2009 Yang L, Calingasan NY, Thomas B, Chaturvedi RK, Kiaei M, Wille EJ, Liby KT, Williams C, Royce D, Risingsong R, Musiek ES, Morrow JD, Sporn M, Beal MF. Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription. Plos One. 4: e5757. PMID 19484125 DOI: 10.1371/Journal.Pone.0005757  0.763
2009 Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. Journal of Neurochemistry. 109: 1427-39. PMID 19476553 DOI: 10.1111/J.1471-4159.2009.06074.X  0.69
2009 Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease. Human Molecular Genetics. 18: 3048-65. PMID 19460884 DOI: 10.1093/Hmg/Ddp243  0.791
2009 Cristóvão AC, Choi DH, Baltazar G, Beal MF, Kim YS. The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxidants & Redox Signaling. 11: 2105-18. PMID 19450058 DOI: 10.1089/Ars.2009.2459  0.494
2009 Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 2459-66. PMID 19346295 DOI: 10.1096/Fj.09-132928  0.666
2009 Liu W, Vives-Bauza C, Acín-Peréz- R, Yamamoto A, Tan Y, Li Y, Magrané J, Stavarache MA, Shaffer S, Chang S, Kaplitt MG, Huang XY, Beal MF, Manfredi G, Li C. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. Plos One. 4: e4597. PMID 19242547 DOI: 10.1371/Journal.Pone.0004597  0.37
2009 Yang L, Zhao K, Calingasan NY, Luo G, Szeto HH, Beal MF. Mitochondria targeted peptides protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Antioxidants & Redox Signaling. 11: 2095-104. PMID 19203217 DOI: 10.1089/Ars.2009.2445  0.659
2009 Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochimica Et Biophysica Acta. 1792: 651-63. PMID 19059336 DOI: 10.1016/J.Bbadis.2008.11.007  0.554
2009 Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochemistry International. 54: 111-8. PMID 19041676 DOI: 10.1016/J.Neuint.2008.10.008  0.397
2009 Karuppagounder SS, Xu H, Shi Q, Chen LH, Pedrini S, Pechman D, Baker H, Beal MF, Gandy SE, Gibson GE. Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiology of Aging. 30: 1587-600. PMID 18406011 DOI: 10.1016/J.Neurobiolaging.2007.12.013  0.409
2009 Dumont M, Wille E, Calingasan NY, Tampellini D, Williams C, Gouras GK, Liby K, Sporn M, Nathan C, Beal MF, Lin MT. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease: (Journal of Neurochemistry (2009) 109 (502-512)) Journal of Neurochemistry. 109: 1192. DOI: 10.1111/J.1471-4159.2009.06053.X  0.674
2008 Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Annals of the New York Academy of Sciences. 1147: 395-412. PMID 19076459 DOI: 10.1196/Annals.1427.027  0.581
2008 Henchcliffe C, Shungu DC, Mao X, Huang C, Nirenberg MJ, Jenkins BG, Beal MF. Multinuclear magnetic resonance spectroscopy for in vivo assessment of mitochondrial dysfunction in Parkinson's disease. Annals of the New York Academy of Sciences. 1147: 206-20. PMID 19076443 DOI: 10.1196/Annals.1427.037  0.349
2008 Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Medicine. 10: 275-90. PMID 19005780 DOI: 10.1007/S12017-008-8053-Y  0.73
2008 Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nature Clinical Practice. Neurology. 4: 600-9. PMID 18978800 DOI: 10.1038/Ncpneuro0924  0.386
2008 Yang Y, Ouyang Y, Yang L, Beal MF, McQuibban A, Vogel H, Lu B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proceedings of the National Academy of Sciences of the United States of America. 105: 7070-5. PMID 18443288 DOI: 10.1073/Pnas.0711845105  0.628
2008 Calingasan NY, Ho DJ, Wille EJ, Campagna MV, Ruan J, Dumont M, Yang L, Shi Q, Gibson GE, Beal MF. Influence of mitochondrial enzyme deficiency on adult neurogenesis in mouse models of neurodegenerative diseases. Neuroscience. 153: 986-96. PMID 18423880 DOI: 10.1016/J.Neuroscience.2008.02.071  0.708
2008 Chaturvedi RK, Beal MF. PPAR: a therapeutic target in Parkinson's disease. Journal of Neurochemistry. 106: 506-18. PMID 18384649 DOI: 10.1111/J.1471-4159.2008.05388.X  0.58
2008 Yang L, Calingasan NY, Lorenzo BJ, Beal MF. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Experimental Neurology. 211: 311-4. PMID 18328479 DOI: 10.1016/J.Expneurol.2007.02.010  0.641
2008 Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Beal MF. Metabolomic profiling to develop blood biomarkers for Parkinson's disease Brain. 131: 389-396. PMID 18222993 DOI: 10.1093/Brain/Awm304  0.309
2008 Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends in Molecular Medicine. 14: 45-53. PMID 18218341 DOI: 10.1016/J.Molmed.2007.12.002  0.356
2008 Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko B, Fisher M, Cho S, Beal MF, Ratan RR. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 163-76. PMID 18171934 DOI: 10.1523/Jneurosci.3200-07.2008  0.629
2008 Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. Journal of Neurochemistry. 104: 1613-21. PMID 17973981 DOI: 10.1111/J.1471-4159.2007.05097.X  0.643
2008 Lorenzl S, Buerger K, Hampel H, Beal MF. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia. International Psychogeriatrics / Ipa. 20: 67-76. PMID 17697439 DOI: 10.1017/S1041610207005790  0.544
2007 Beal MF. Mitochondria and neurodegeneration. Novartis Foundation Symposium. 287: 183-92; discussion 1. PMID 18074639 DOI: 10.1002/9780470725207.Ch13  0.413
2007 Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 12908-15. PMID 18032664 DOI: 10.1523/Jneurosci.4318-07.2007  0.666
2007 Strand AD, Baquet ZC, Aragaki AK, Holmans P, Yang L, Cleren C, Beal MF, Jones L, Kooperberg C, Olson JM, Jones KR. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 11758-68. PMID 17959817 DOI: 10.1523/Jneurosci.2461-07.2007  0.664
2007 Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K. A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone). Journal of Clinical Pharmacology. 47: 1580-6. PMID 17925590 DOI: 10.1177/0091270007307571  0.425
2007 Manfredi G, Beal MF. Merging mitochondria for neuronal survival. Nature Medicine. 13: 1140-1. PMID 17917656 DOI: 10.1038/Nm1007-1140  0.319
2007 Thomas B, Beal MF. Parkinson's disease. Human Molecular Genetics. 16: R183-94. PMID 17911161 DOI: 10.1093/hmg/ddm159  0.522
2007 Inoue H, Lin L, Lee X, Shao Z, Mendes S, Snodgrass-Belt P, Sweigard H, Engber T, Pepinsky B, Yang L, Beal MF, Mi S, Isacson O. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proceedings of the National Academy of Sciences of the United States of America. 104: 14430-5. PMID 17726113 DOI: 10.1073/pnas.0700901104  0.628
2007 Petri S, Calingasan NY, Alsaied OA, Wille E, Kiaei M, Friedman JE, Baranova O, Chavez JC, Beal MF. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 102: 991-1000. PMID 17630988 DOI: 10.1111/J.1471-4159.2007.04604.X  0.567
2007 Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J, Heissig B, Rafii S, Lorenzl S, Beal MF. Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Experimental Neurology. 205: 74-81. PMID 17362932 DOI: 10.1016/J.Expneurol.2007.01.036  0.796
2007 Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, Sugama S, Cho BP, Hwang O, Browne SE, Kim SY, Hong JS, Beal MF, Joh TH. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 179-87. PMID 17116747 DOI: 10.1096/Fj.06-5865Com  0.804
2007 Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle & Nerve. 35: 235-42. PMID 17080429 DOI: 10.1002/Mus.20688  0.327
2007 Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Erratum: Corrigendum: Functional engraftment of human ES cell–derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes Nature Medicine. 13: 385-385. DOI: 10.1038/nm0307-385b  0.552
2006 Beal MF, Bossy-Wetzel E, Finkbeiner S, Fiskum G, Giasson B, Johnson C, Khachaturian ZS, Lee VM, Nicholls D, Reddy H, Reynolds I, Teplow DB, Thal LJ, Trojanowski JQ, Walsh DM, et al. Common threads in neurodegenerative disorders of aging. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 322-6. PMID 19595906 DOI: 10.1016/J.Jalz.2006.08.008  0.405
2006 Lin MT, Beal MF. Alzheimer's APP mangles mitochondria. Nature Medicine. 12: 1241-3. PMID 17088888 DOI: 10.1038/Nm1106-1241  0.539
2006 McGill JK, Beal MF. PGC-1alpha, a new therapeutic target in Huntington's disease? Cell. 127: 465-8. PMID 17081970 DOI: 10.1016/J.Cell.2006.10.023  0.327
2006 Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nature Medicine. 12: 1259-68. PMID 17057709 DOI: 10.1038/Nm1495  0.605
2006 Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 443: 787-95. PMID 17051205 DOI: 10.1038/Nature05292  0.568
2006 Browne SE, Beal MF. Oxidative damage in Huntington's disease pathogenesis. Antioxidants & Redox Signaling. 8: 2061-73. PMID 17034350 DOI: 10.1089/Ars.2006.8.2061  0.597
2006 Saydoff JA, Garcia RA, Browne SE, Liu L, Sheng J, Brenneman D, Hu Z, Cardin S, Gonzalez A, von Borstel RW, Gregorio J, Burr H, Beal MF. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease. Neurobiology of Disease. 24: 455-65. PMID 17011205 DOI: 10.1016/J.Nbd.2006.08.011  0.572
2006 Petri S, Kiaei M, Damiano M, Hiller A, Wille E, Manfredi G, Calingasan NY, Szeto HH, Beal MF. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 98: 1141-8. PMID 16895581 DOI: 10.1111/J.1471-4159.2006.04018.X  0.741
2006 Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proceedings of the National Academy of Sciences of the United States of America. 103: 10793-8. PMID 16818890 DOI: 10.1073/Pnas.0602493103  0.646
2006 Kwong JQ, Beal MF, Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. Journal of Neurochemistry. 97: 1659-75. PMID 16805775 DOI: 10.1111/J.1471-4159.2006.03990.X  0.404
2006 Browne SE, Yang L, DiMauro JP, Fuller SW, Licata SC, Beal MF. Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS. Neurobiology of Disease. 22: 599-610. PMID 16616851 DOI: 10.1016/J.Nbd.2006.01.001  0.695
2006 Lorenzl S, Narr S, Angele B, Krell HW, Gregorio J, Kiaei M, Pfister HW, Beal MF. The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. Experimental Neurology. 200: 166-71. PMID 16516196 DOI: 10.1016/J.Expneurol.2006.01.026  0.786
2006 Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 2467-73. PMID 16510725 DOI: 10.1523/Jneurosci.5253-05.2006  0.789
2006 Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 66: 250-2. PMID 16434666 DOI: 10.1212/01.Wnl.0000194318.74946.B6  0.456
2006 Hervias I, Beal MF, Manfredi G. Mitochondrial dysfunction and amyotrophic lateral sclerosis. Muscle & Nerve. 33: 598-608. PMID 16372325 DOI: 10.1002/Mus.20489  0.396
2006 Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease. 21: 541-8. PMID 16298531 DOI: 10.1016/J.Nbd.2005.08.018  0.811
2006 Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease. 22: 40-9. PMID 16289867 DOI: 10.1016/J.Nbd.2005.09.013  0.804
2005 Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH, Kaddurah-Daouk R. Metabolomic analysis and signatures in motor neuron disease. Metabolomics : Official Journal of the Metabolomic Society. 1: 101-108. PMID 18820733 DOI: 10.1007/S11306-005-4810-1  0.355
2005 Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neuro-Degenerative Diseases. 2: 246-54. PMID 16909005 DOI: 10.1159/000090364  0.802
2005 Kim SY, Marekov L, Bubber P, Browne SE, Stavrovskaya I, Lee J, Steinert PM, Blass JP, Beal MF, Gibson GE, Cooper AJ. Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain. Neurochemical Research. 30: 1245-55. PMID 16341586 DOI: 10.1007/S11064-005-8796-X  0.547
2005 Li C, Beal MF. Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 102: 16535-6. PMID 16275903 DOI: 10.1073/Pnas.0508350102  0.377
2005 Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Research. Brain Research Reviews. 49: 618-32. PMID 16269322 DOI: 10.1016/J.Brainresrev.2005.03.004  0.329
2005 Nathan C, Calingasan N, Nezezon J, Ding A, Lucia MS, La Perle K, Fuortes M, Lin M, Ehrt S, Kwon NS, Chen J, Vodovotz Y, Kipiani K, Beal MF. Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. The Journal of Experimental Medicine. 202: 1163-9. PMID 16260491 DOI: 10.1084/Jem.20051529  0.793
2005 Cantuti-Castelvetri I, Lin MT, Zheng K, Keller-McGandy CE, Betensky RA, Johns DR, Beal MF, Standaert DG, Simon DK. Somatic mitochondrial DNA mutations in single neurons and glia. Neurobiology of Aging. 26: 1343-55. PMID 16243605 DOI: 10.1016/J.Neurobiolaging.2004.11.008  0.605
2005 Beal MF. Mitochondria take center stage in aging and neurodegeneration. Annals of Neurology. 58: 495-505. PMID 16178023 DOI: 10.1002/Ana.20624  0.422
2005 Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang L, Beal MF, Nishimura I, Wakamatsu K, Ito S, Takahashi R, Lu B. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proceedings of the National Academy of Sciences of the United States of America. 102: 13670-5. PMID 16155123 DOI: 10.1073/Pnas.0504610102  0.609
2005 Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry. 95: 553-62. PMID 16135087 DOI: 10.1111/J.1471-4159.2005.03411.X  0.49
2005 Cleren C, Starkov AA, Calingasan NY, Lorenzo BJ, Chen J, Beal MF. Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurobiology of Disease. 20: 701-8. PMID 16126396 DOI: 10.1016/J.Nbd.2005.05.022  0.422
2005 Son JH, Kawamata H, Yoo MS, Kim DJ, Lee YK, Kim S, Dawson TM, Zhang H, Sulzer D, Yang L, Beal MF, Degiorgio LA, Chun HS, Baker H, Peng C. Neurotoxicity and behavioral deficits associated with Septin 5 accumulation in dopaminergic neurons. Journal of Neurochemistry. 94: 1040-53. PMID 16092945 DOI: 10.1111/J.1471-4159.2005.03257.X  0.657
2005 Cleren C, Calingasan NY, Chen J, Beal MF. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. Journal of Neurochemistry. 94: 995-1004. PMID 16092942 DOI: 10.1111/J.1471-4159.2005.03253.X  0.434
2005 Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Annals of Neurology. 58: 258-65. PMID 16049935 DOI: 10.1002/Ana.20552  0.38
2005 Aguirre N, Beal MF, Matson WR, Bogdanov MB. Increased oxidative damage to DNA in an animal model of amyotrophic lateral sclerosis. Free Radical Research. 39: 383-8. PMID 16028363 DOI: 10.1080/10715760400027979  0.6
2005 Kleiner-Fisman G, Calingasan NY, Putt M, Chen J, Beal MF, Lang AE. Alterations of striatal neurons in benign hereditary chorea. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 1353-7. PMID 15986422 DOI: 10.1002/Mds.20577  0.322
2005 Gibson GE, Blass JP, Beal MF, Bunik V. The alpha-ketoglutarate-dehydrogenase complex: a mediator between mitochondria and oxidative stress in neurodegeneration. Molecular Neurobiology. 31: 43-63. PMID 15953811 DOI: 10.1385/Mn:31:1-3:043  0.413
2005 Calingasan NY, Chen J, Kiaei M, Beal MF. Beta-amyloid 42 accumulation in the lumbar spinal cord motor neurons of amyotrophic lateral sclerosis patients. Neurobiology of Disease. 19: 340-7. PMID 15837590 DOI: 10.1016/J.Nbd.2005.01.012  0.318
2005 Kiaei M, Kipiani K, Petri S, Choi DK, Chen J, Calingasan NY, Beal MF. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 93: 403-11. PMID 15816863 DOI: 10.1111/J.1471-4159.2005.03024.X  0.791
2005 Kim YS, Kim SS, Cho JJ, Choi DH, Hwang O, Shin DH, Chun HS, Beal MF, Joh TH. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 3701-11. PMID 15814801 DOI: 10.1523/Jneurosci.4346-04.2005  0.544
2005 Vijayvergiya C, Beal MF, Buck J, Manfredi G. Mutant superoxide dismutase 1 forms aggregates in the brain mitochondrial matrix of amyotrophic lateral sclerosis mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2463-70. PMID 15758154 DOI: 10.1523/Jneurosci.4385-04.2005  0.398
2005 Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Current Drug Targets. Cns and Neurological Disorders. 4: 41-50. PMID 15723612 DOI: 10.2174/1568007053005091  0.304
2005 Beal MF. Oxidative damage as an early marker of Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging. 26: 585-6. PMID 15708432 DOI: 10.1016/J.Neurobiolaging.2004.09.022  0.312
2005 Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Experimental Neurology. 191: 331-6. PMID 15649489 DOI: 10.1016/J.Expneurol.2004.10.007  0.764
2005 Andrews ZB, Horvath B, Barnstable CJ, Elsworth J, Elseworth J, Yang L, Beal MF, Roth RH, Matthews RT, Horvath TL. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 184-91. PMID 15634780 DOI: 10.1523/Jneurosci.4269-04.2005  0.628
2005 Yang L, Calingasan NY, Chen J, Ley JJ, Becker DA, Beal MF. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Experimental Neurology. 191: 86-93. PMID 15589515 DOI: 10.1016/J.Expneurol.2004.07.012  0.67
2005 Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63. PMID 15494404 DOI: 10.1074/Jbc.M410210200  0.81
2004 Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Medicine. 6: 87-92. PMID 15970626 DOI: 10.1385/Nmm:6:2-3:087  0.821
2004 Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Medicine. 5: 235-41. PMID 15626823 DOI: 10.1385/Nmm:5:3:235  0.813
2004 Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 10335-42. PMID 15548647 DOI: 10.1523/Jneurosci.2599-04.2004  0.566
2004 Martinat C, Shendelman S, Jonason A, Leete T, Beal MF, Yang L, Floss T, Abeliovich A. Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism. Plos Biology. 2: e327. PMID 15502868 DOI: 10.1371/Journal.Pbio.0020327  0.648
2004 Yang L, Sugama S, Mischak RP, Kiaei M, Bizat N, Brouillet E, Joh TH, Beal MF. A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiology of Disease. 17: 250-9. PMID 15474362 DOI: 10.1016/J.Nbd.2004.07.021  0.747
2004 Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. Journal of Bioenergetics and Biomembranes. 36: 381-6. PMID 15377876 DOI: 10.1023/B:Jobb.0000041772.74810.92  0.407
2004 Kristal BS, Stavrovskaya IG, Narayanan MV, Krasnikov BF, Brown AM, Beal MF, Friedlander RM. The mitochondrial permeability transition as a target for neuroprotection. Journal of Bioenergetics and Biomembranes. 36: 309-12. PMID 15377863 DOI: 10.1023/B:Jobb.0000041759.35731.70  0.337
2004 Kiaei M, Bush AI, Morrison BM, Morrison JH, Cherny RA, Volitakis I, Beal MF, Gordon JW. Genetically decreased spinal cord copper concentration prolongs life in a transgenic mouse model of amyotrophic lateral sclerosis. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 7945-50. PMID 15356208 DOI: 10.1523/Jneurosci.2000-04.2004  0.327
2004 Starkov AA, Fiskum G, Chinopoulos C, Lorenzo BJ, Browne SE, Patel MS, Beal MF. Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 7779-88. PMID 15356189 DOI: 10.1523/Jneurosci.1899-04.2004  0.522
2004 Stavrovskaya IG, Narayanan MV, Zhang W, Krasnikov BF, Heemskerk J, Young SS, Blass JP, Brown AM, Beal MF, Friedlander RM, Kristal BS. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. The Journal of Experimental Medicine. 200: 211-22. PMID 15263028 DOI: 10.1084/Jem.20032053  0.325
2004 Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proceedings of the National Academy of Sciences of the United States of America. 101: 10726-31. PMID 15247418 DOI: 10.1073/Pnas.0403649101  0.31
2004 Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, Brown RH, Kristal BS, Ferrante RJ, Friedlander RM. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 5909-12. PMID 15229238 DOI: 10.1523/Jneurosci.1278-04.2004  0.385
2004 Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nature Reviews. Neuroscience. 5: 373-84. PMID 15100720 DOI: 10.1038/Nrn1386  0.377
2004 Lorenzl S, Calingasan N, Yang L, Albers DS, Shugama S, Gregorio J, Krell HW, Chirichigno J, Joh T, Beal MF. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuromolecular Medicine. 5: 119-32. PMID 15075439 DOI: 10.1385/Nmm:5:2:119  0.721
2004 Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, Yang L, Wieringa B, Beal MF. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease. 15: 610-7. PMID 15056469 DOI: 10.1016/J.Nbd.2003.12.014  0.741
2004 Beal MF. Therapeutic effects of coenzyme Q10 in neurodegenerative diseases. Methods in Enzymology. 382: 473-87. PMID 15047118 DOI: 10.1016/S0076-6879(04)82026-3  0.446
2004 Browne SE, Beal MF. The energetics of Huntington's disease. Neurochemical Research. 29: 531-46. PMID 15038601 DOI: 10.1023/B:Nere.0000014824.04728.Dd  0.58
2004 Browne SE, Roberts LJ, Dennery PA, Doctrow SR, Beal MF, Barlow C, Levine RL. Treatment with a catalytic antioxidant corrects the neurobehavioral defect in ataxia-telangiectasia mice. Free Radical Biology & Medicine. 36: 938-42. PMID 15019978 DOI: 10.1016/J.Freeradbiomed.2004.01.003  0.562
2004 Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. Journal of Neurochemistry. 88: 1352-60. PMID 15009635 DOI: 10.1046/J.1471-4159.2003.02263.X  0.83
2004 Lorenzl S, Albers DS, Chirichigno JW, Augood SJ, Beal MF. Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. Journal of the Neurological Sciences. 218: 39-45. PMID 14759631 DOI: 10.1016/J.Jns.2003.10.015  0.557
2004 Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 88: 576-82. PMID 14720207 DOI: 10.1046/J.1471-4159.2003.02160.X  0.807
2004 UluÄŸ AM, Grünewald T, Lin MT, Kamal AK, Filippi CG, Zimmerman RD, Beal MF. Diffusion tensor imaging in the diagnosis of primary lateral sclerosis. Journal of Magnetic Resonance Imaging : Jmri. 19: 34-9. PMID 14696218 DOI: 10.1002/Jmri.10433  0.451
2004 Simon DK, Lin MT, Zheng L, Liu GJ, Ahn CH, Kim LM, Mauck WM, Twu F, Beal MF, Johns DR. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiology of Aging. 25: 71-81. PMID 14675733 DOI: 10.1016/S0197-4580(03)00037-X  0.624
2004 Beal MF. Bioenergetics in the pathogenesis of neurodegeneration Journal of Neurochemistry. 77: iv-iv. DOI: 10.1111/J.1471-4159.2001.00001.X  0.44
2004 Beal MF. PL-2-1 Oxidative mechanisms, inflammation, and Alzheimer's disease pathogenesis Neurobiology of Aging. 25: S24. DOI: 10.1016/S0197-4580(04)80076-9  0.345
2003 Beal MF, Shults CW. Effects of Coenzyme Q10 in Huntington's disease and early Parkinson's disease. Biofactors (Oxford, England). 18: 153-61. PMID 14695931 DOI: 10.1002/Biof.5520180218  0.334
2003 Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 21: 191-8. PMID 14645986 DOI: 10.1385/Jmn:21:3:191  0.814
2003 Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jørgensen HA. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience. 122: 717-25. PMID 14622915 DOI: 10.1016/J.Neuroscience.2003.08.058  0.354
2003 Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF, Albers DS. Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of Neuroscience Research. 74: 278-85. PMID 14515357 DOI: 10.1002/Jnr.10709  0.791
2003 Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K, Perrier AL, Bruses J, Rubio ME, Topf N, Tabar V, Harrison NL, Beal MF, Moore MA, Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nature Biotechnology. 21: 1200-7. PMID 14502203 DOI: 10.1038/Nbt870  0.581
2003 Diano S, Matthews RT, Patrylo P, Yang L, Beal MF, Barnstable CJ, Horvath TL. Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning. Endocrinology. 144: 5014-21. PMID 12960023 DOI: 10.1210/En.2003-0667  0.639
2003 Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Annals of the New York Academy of Sciences. 991: 120-31. PMID 12846981 DOI: 10.1111/J.1749-6632.2003.Tb07470.X  0.351
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 86: 267-72. PMID 12807446 DOI: 10.1046/J.1471-4159.2003.T01-1-01868.X  0.823
2003 Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of Neurochemistry. 85: 1359-67. PMID 12787055 DOI: 10.1046/J.1471-4159.2003.01706.X  0.642
2003 Lorenzl S, De Pasquale G, Segal AZ, Beal MF. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke; a Journal of Cerebral Circulation. 34: e37-8; author reply . PMID 12750528 DOI: 10.1161/01.Str.0000075563.45920.24  0.55
2003 Zhang L, Ulug AM, Zimmerman RD, Lin MT, Rubin M, Beal MF. The diagnostic utility of FLAIR imaging in clinically verified amyotrophic lateral sclerosis. Journal of Magnetic Resonance Imaging : Jmri. 17: 521-7. PMID 12720261 DOI: 10.1002/Jmri.10293  0.48
2003 Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochemistry International. 43: 191-6. PMID 12689599 DOI: 10.1016/S0197-0186(03)00004-4  0.567
2003 Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron. 37: 899-909. PMID 12670420 DOI: 10.1016/S0896-6273(03)00126-0  0.589
2003 Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Annals of Neurology. 53: S39-47; discussion S. PMID 12666097 DOI: 10.1002/Ana.10479  0.365
2003 Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, Beal MF. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 85: 142-50. PMID 12641736 DOI: 10.1046/J.1471-4159.2003.01639.X  0.709
2003 Gajewski CD, Lin MT, Cudkowicz ME, Beal MF, Manfredi G. Mitochondrial DNA from platelets of sporadic ALS patients restores normal respiratory functions in rho(0) cells. Experimental Neurology. 179: 229-35. PMID 12618129 DOI: 10.1016/S0014-4886(02)00022-5  0.534
2003 Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, Beal MF. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. Journal of the Neurological Sciences. 207: 71-6. PMID 12614934 DOI: 10.1016/S0022-510X(02)00398-2  0.551
2003 Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Research. 964: 288-94. PMID 12576189 DOI: 10.1016/S0006-8993(02)04085-4  0.711
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Erratum: Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease (Journal of Neurochemistry (2003) 86 (267-272)) Journal of Neurochemistry. 87. DOI: 10.1046/J.1471-4159.2003.01868.X  0.805
2002 Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiology of Disease. 11: 410-24. PMID 12586550 DOI: 10.1006/Nbdi.2002.0562  0.561
2002 Browne SE, Beal MF. Toxin-induced mitochondrial dysfunction. International Review of Neurobiology. 53: 243-79. PMID 12512343 DOI: 10.1016/S0074-7742(02)53010-5  0.548
2002 Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Experimental Neurology. 178: 13-20. PMID 12460604 DOI: 10.1006/Exnr.2002.8019  0.777
2002 Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. The American Journal of Pathology. 161: 1869-79. PMID 12414533 DOI: 10.1016/S0002-9440(10)64463-X  0.589
2002 Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ. Therapeutic effects of cystamine in a murine model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8942-50. PMID 12388601 DOI: 10.1523/Jneurosci.22-20-08942.2002  0.422
2002 Chirichigno JW, Manfredi G, Beal MF, Albers DS. Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids. Brain Research. 951: 31-5. PMID 12231453 DOI: 10.1016/S0006-8993(02)03101-3  0.358
2002 Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radical Biology & Medicine. 33: 620-6. PMID 12208348 DOI: 10.1016/S0891-5849(02)00807-9  0.327
2002 Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Medicine. 1: 183-95. PMID 12095160 DOI: 10.1385/Nmm:1:3:183  0.398
2002 Dedeoglu A, Ferrante RJ, Andreassen OA, Dillmann WH, Beal MF. Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid. Experimental Neurology. 176: 262-5. PMID 12093104 DOI: 10.1006/Exnr.2002.7933  0.476
2002 Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radical Research. 36: 455-60. PMID 12069110 DOI: 10.1080/10715760290021315  0.447
2002 Mattiazzi M, D'Aurelio M, Gajewski CD, Martushova K, Kiaei M, Beal MF, Manfredi G. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. The Journal of Biological Chemistry. 277: 29626-33. PMID 12050154 DOI: 10.1074/Jbc.M203065200  0.426
2002 Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Archives of Neurology. 59: 794-8. PMID 12020262 DOI: 10.1001/Archneur.59.5.794  0.597
2002 Wendt S, Dedeoglu A, Speer O, Wallimann T, Beal MF, Andreassen OA. Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Radical Biology & Medicine. 32: 920-6. PMID 11978494 DOI: 10.1016/S0891-5849(02)00784-0  0.505
2002 Beal MF. Oxidatively modified proteins in aging and disease. Free Radical Biology & Medicine. 32: 797-803. PMID 11978481 DOI: 10.1016/S0891-5849(02)00780-3  0.376
2002 Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 1592-9. PMID 11880489 DOI: 10.1523/Jneurosci.22-05-01592.2002  0.492
2002 Cantuti-Castelvetri I, Keller-McGandy CE, Albers DS, Beal MF, Vonsattel JP, Standaert DG, Augood SJ. Expression and activity of antioxidants in the brain in progressive supranuclear palsy. Brain Research. 930: 170-81. PMID 11879807 DOI: 10.1016/S0006-8993(02)02244-8  0.338
2002 Albers DS, Beal MF. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochemistry International. 40: 559-64. PMID 11850113 DOI: 10.1016/S0197-0186(01)00126-7  0.401
2002 Wiedemann FR, Manfredi G, Mawrin C, Beal MF, Schon EA. Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients. Journal of Neurochemistry. 80: 616-25. PMID 11841569 DOI: 10.1046/J.0022-3042.2001.00731.X  0.331
2002 Vives-Bauza C, Andreu AL, Manfredi G, Beal MF, Janetzky B, Gruenewald TH, Lin MT. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochemical and Biophysical Research Communications. 290: 1593-601. PMID 11820805 DOI: 10.1006/Bbrc.2002.6388  0.512
2002 Lin MT, Simon DK, Ahn CH, Kim LM, Beal MF. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Human Molecular Genetics. 11: 133-45. PMID 11809722 DOI: 10.1093/Hmg/11.2.133  0.61
2001 Fanò G, Mecocci P, Vecchiet J, Belia S, Fulle S, Polidori MC, Felzani G, Senin U, Vecchiet L, Beal MF. Age and sex influence on oxidative damage and functional status in human skeletal muscle. Journal of Muscle Research and Cell Motility. 22: 345-51. PMID 11808774 DOI: 10.1023/A:1013122805060  0.476
2001 Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 79: 1246-9. PMID 11752065 DOI: 10.1046/J.1471-4159.2001.00689.X  0.516
2001 Park LC, Albers DS, Xu H, Lindsay JG, Beal MF, Gibson GE. Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. Journal of Neuroscience Research. 66: 1028-34. PMID 11746433 DOI: 10.1002/Jnr.10062  0.378
2001 Jeitner TM, Bogdanov MB, Matson WR, Daikhin Y, Yudkoff M, Folk JE, Steinman L, Browne SE, Beal MF, Blass JP, Cooper AJ. N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease. Journal of Neurochemistry. 79: 1109-12. PMID 11739625 DOI: 10.1046/J.1471-4159.2001.00673.X  0.504
2001 Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF, Andersen JK. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 9519-28. PMID 11739563 DOI: 10.1523/Jneurosci.21-24-09519.2001  0.638
2001 Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport. 12: 3371-3. PMID 11711888 DOI: 10.1097/00001756-200110290-00044  0.424
2001 Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Molecular Neuroscience : Mn. 17: 89-96. PMID 11665866 DOI: 10.1385/Jmn:17:1:89  0.381
2001 D'Aurelio M, Pallotti F, Barrientos A, Gajewski CD, Kwong JQ, Bruno C, Beal MF, Manfredi G. In vivo regulation of oxidative phosphorylation in cells harboring a stop-codon mutation in mitochondrial DNA-encoded cytochrome c oxidase subunit I. The Journal of Biological Chemistry. 276: 46925-32. PMID 11595737 DOI: 10.1074/Jbc.M106429200  0.304
2001 Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE, Beal MF. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Annals of Neurology. 50: 112-7. PMID 11456300 DOI: 10.1002/Ana.1085  0.527
2001 Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiology of Disease. 8: 479-91. PMID 11447996 DOI: 10.1006/Nbdi.2001.0406  0.778
2001 Gouras GK, Beal MF. Metal chelator decreases Alzheimer beta-amyloid plaques. Neuron. 30: 641-2. PMID 11430794 DOI: 10.1016/S0896-6273(01)00330-0  0.576
2001 Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Annals of Neurology. 49: 561-74. PMID 11357946 DOI: 10.1002/Ana.1028  0.369
2001 Simon DK, Lin MT, Ahn CH, Liu GJ, Gibson GE, Beal MF, Johns DR. Low mutational burden of individual acquired mitochondrial DNA mutations in brain. Genomics. 73: 113-6. PMID 11352572 DOI: 10.1006/Geno.2001.6515  0.573
2001 Beal MF. Experimental models of Parkinson's disease. Nature Reviews. Neuroscience. 2: 325-34. PMID 11331916 DOI: 10.1038/35072550  0.396
2001 Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 2561-70. PMID 11306609  0.664
2001 Andreassen OA, Jenkins BG, Dedeoglu A, Ferrante KL, Bogdanov MB, Kaddurah-Daouk R, Beal MF. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. Journal of Neurochemistry. 77: 383-90. PMID 11299300 DOI: 10.1046/J.1471-4159.2001.00188.X  0.483
2001 Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D, Szabo C, Beal MF. Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Experimental Neurology. 168: 419-24. PMID 11259130 DOI: 10.1006/Exnr.2001.7633  0.731
2001 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Dedeoglu A, Albers DS, Kowall NW, Beal MF. Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid. Experimental Neurology. 168: 356-63. PMID 11259123 DOI: 10.1006/Exnr.2001.7627  0.685
2001 Albers DS, Swerdlow RH, Manfredi G, Gajewski C, Yang L, Parker WD, Beal MF. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Experimental Neurology. 168: 196-8. PMID 11170735 DOI: 10.1006/Exnr.2000.7607  0.611
2001 Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, Carlson EJ, Epstein CJ, Beal MF. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Experimental Neurology. 167: 189-95. PMID 11161607 DOI: 10.1006/Exnr.2000.7525  0.693
2001 Beal MF, Hantraye P. Novel therapies in the search for a cure for Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 98: 3-4. PMID 11136240 DOI: 10.1073/Pnas.98.1.3  0.331
2001 Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, Xu H. Stimulation of β-Amyloid Precursor Protein Trafficking by Insulin Reduces Intraneuronal β-Amyloid and Requires Mitogen-Activated Protein Kinase Signaling The Journal of Neuroscience. 21: 2561-2570. DOI: 10.1523/Jneurosci.21-08-02561.2001  0.689
2000 Friedlich AL, Beal MF. Prospects for redox-based therapy in neurodegenerative diseases. Neurotoxicity Research. 2: 229-37. PMID 16787843 DOI: 10.1007/Bf03033796  0.712
2000 Beal MF, Palomo T, Kostrzewa RM, Archer T. Neuroprotective and neurorestorative strategies for neuronal injury. Neurotoxicity Research. 2: 71-84. PMID 16787833 DOI: 10.1007/Bf03033786  0.429
2000 Fulle S, Mecocci P, Fanó G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radical Biology & Medicine. 29: 1252-9. PMID 11118815 DOI: 10.1016/S0891-5849(00)00419-6  0.583
2000 Montine TJ, Shinobu L, Montine KS, Roberts LJ, Kowall NW, Beal MF, Morrow JD. No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Annals of Neurology. 48: 950. PMID 11117557 DOI: 10.1002/1531-8249(200012)48:6<950::Aid-Ana23>3.0.Co;2-F  0.684
2000 Schulz JB, Dehmer T, Schöls L, Mende H, Hardt C, Vorgerd M, Bürk K, Matson W, Dichgans J, Beal MF, Bogdanov MB. Oxidative stress in patients with Friedreich ataxia. Neurology. 55: 1719-21. PMID 11113228 DOI: 10.1212/Wnl.55.11.1719  0.381
2000 Kuntz C, Kinoshita Y, Beal MF, Donehower LA, Morrison RS. Absence of p53: no effect in a transgenic mouse model of familial amyotrophic lateral sclerosis. Experimental Neurology. 165: 184-90. PMID 10964497 DOI: 10.1006/Exnr.2000.7464  0.349
2000 Albers DS, Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. Journal of Neural Transmission. Supplementum. 59: 133-54. PMID 10961426 DOI: 10.1007/978-3-7091-6781-6_16  0.427
2000 Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 11: 2491-3. PMID 10943709 DOI: 10.1097/00001756-200008030-00029  0.656
2000 Andreassen OA, Ferrante RJ, Hughes DB, Klivenyi P, Dedeoglu A, Ona VO, Friedlander RM, Beal MF. Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. Journal of Neurochemistry. 75: 847-52. PMID 10899963 DOI: 10.1046/J.1471-4159.2000.0750847.X  0.661
2000 Manfredi G, Beal MF. The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathology (Zurich, Switzerland). 10: 462-72. PMID 10885665 DOI: 10.1111/J.1750-3639.2000.Tb00278.X  0.381
2000 Beal MF. Mitochondria and the pathogenesis of ALS. Brain : a Journal of Neurology. 123: 1291-2. PMID 10869044 DOI: 10.1093/Brain/123.7.1291  0.336
2000 Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends in Neurosciences. 23: 298-304. PMID 10856939 DOI: 10.1016/S0166-2236(00)01584-8  0.4
2000 Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 4389-97. PMID 10844007 DOI: 10.1523/Jneurosci.20-12-04389.2000  0.535
2000 Beal MF. Limited-time exposure to mitochondrial toxins may lead to chronic progressive neurodegenerative diseases. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 434-5. PMID 10830405 DOI: 10.1002/1531-8257(200005)15:3<434::Aid-Mds1002>3.0.Co;2-Q  0.327
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D, Beal MF. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport. 11: 1265-8. PMID 10817604 DOI: 10.1097/00001756-200004270-00024  0.779
2000 Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. Journal of Neurochemistry. 74: 2108-19. PMID 10800956 DOI: 10.1046/J.1471-4159.2000.0742108.X  0.664
2000 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Shinobu LA, Epstein CJ, Beal MF. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology. 47: 447-55. PMID 10762155 DOI: 10.1002/1531-8249(200004)47:4<447::Aid-Ana7>3.0.Co;2-R  0.811
2000 Malcon C, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Research. 860: 195-8. PMID 10727643 DOI: 10.1016/S0006-8993(00)02038-2  0.781
2000 Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 11: 211-3. PMID 10683860 DOI: 10.1097/00001756-200001170-00041  0.549
2000 Simon DK, Mayeux R, Marder K, Kowall NW, Beal MF, Johns DR. Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology. 54: 703-9. PMID 10680807 DOI: 10.1212/Wnl.54.3.703  0.412
2000 Albers DS, Augood SJ, Park LC, Browne SE, Martin DM, Adamson J, Hutton M, Standaert DG, Vonsattel JP, Gibson GE, Beal MF. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. Journal of Neurochemistry. 74: 878-81. PMID 10646541 DOI: 10.1046/J.1471-4159.2000.740878.X  0.551
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 1-7. PMID 10627575 DOI: 10.1523/Jneurosci.20-01-00001.2000  0.806
2000 Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease The Journal of Neuroscience. 20: 4389-4397. DOI: 10.1523/JNEUROSCI.20-12-04389.2000  0.427
2000 Park LC, Albers DS, Beal M, Gibson GE. Mitochondrial impairment in cerebellum from patients with progressive supranuclear palsy Neurobiology of Aging. 21: 79. DOI: 10.1016/S0197-4580(00)82577-4  0.313
2000 Gasparini L, Gouras GK, Wang R, Gross RS, Beal M, Greengard P, Xu H. Insulin-regulated β-amyloid protein trafficking: Stimulated secretion and reduced intracellular accumulation of Aβ in neuronal cell cultures Neurobiology of Aging. 21: 183. DOI: 10.1016/S0197-4580(00)82165-X  0.688
2000 Kaddurah-Daouk R, Matthews R, Beal MF. Amyotrophic lateral sclerosis: Transgenic model and novel neuroprotective agent Neuroscience Research Communications. 26: 215-226. DOI: 10.1002/1520-6769(200005/06)26:3<215::Aid-Nrc9>3.0.Co;2-Z  0.448
1999 Beal MF. Mitochondria, NO and neurodegeneration. Biochemical Society Symposium. 66: 43-54. PMID 10989656 DOI: 10.1042/Bss0660043  0.394
1999 Grünewald T, Beal MF. Bioenergetics in Huntington's disease. Annals of the New York Academy of Sciences. 893: 203-13. PMID 10672239 DOI: 10.1111/J.1749-6632.1999.Tb07827.X  0.423
1999 Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ. Huntington aggregates may not predict neuronal death in Huntington's disease. Annals of Neurology. 46: 842-9. PMID 10589536 DOI: 10.1002/1531-8249(199912)46:6<842::Aid-Ana6>3.0.Co;2-O  0.351
1999 Grünewald T, Beal MF. NOS knockouts and neuroprotection. Nature Medicine. 5: 1354-5. PMID 10581072 DOI: 10.1038/70918  0.416
1999 Simon DK, Pulst SM, Sutton JP, Browne SE, Beal MF, Johns DR. Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology. 53: 1787-93. PMID 10563629 DOI: 10.1212/Wnl.53.8.1787  0.586
1999 Brouillet E, Condé F, Beal MF, Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Progress in Neurobiology. 59: 427-68. PMID 10515664 DOI: 10.1016/S0301-0082(99)00005-2  0.608
1999 Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neuroscience Letters. 272: 53-6. PMID 10507541 DOI: 10.1016/S0304-3940(99)00578-9  0.645
1999 Cherubini A, Beal MF, Frei B. Black tea increases the resistance of human plasma to lipid peroxidation in vitro, but not ex vivo. Free Radical Biology & Medicine. 27: 381-7. PMID 10468212 DOI: 10.1016/S0891-5849(99)00064-7  0.462
1999 Dautry C, Condé F, Brouillet E, Mittoux V, Beal MF, Bloch G, Hantraye P. Serial 1H-NMR spectroscopy study of metabolic impairment in primates chronically treated with the succinate dehydrogenase inhibitor 3-nitropropionic acid. Neurobiology of Disease. 6: 259-68. PMID 10448053 DOI: 10.1006/Nbdi.1999.0244  0.588
1999 Albers DS, Augood SJ, Martin DM, Standaert DG, Vonsattel JP, Beal MF. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. Journal of Neurochemistry. 73: 881-4. PMID 10428088 DOI: 10.1046/J.1471-4159.1999.0730881.X  0.307
1999 Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors (Oxford, England). 9: 267-72. PMID 10416040 DOI: 10.1002/Biof.5520090223  0.374
1999 Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors (Oxford, England). 9: 261-6. PMID 10416039 DOI: 10.1002/Biof.5520090222  0.437
1999 Lezza AM, Mecocci P, Cormio A, Beal MF, Cherubini A, Cantatore P, Senin U, Gadaleta MN. Mitochondrial DNA 4977 bp deletion and OH8dG levels correlate in the brain of aged subjects but not Alzheimer's disease patients. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 13: 1083-8. PMID 10336891 DOI: 10.1096/Fasebj.13.9.1083  0.623
1999 Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Experimental Neurology. 157: 142-9. PMID 10222117 DOI: 10.1006/Exnr.1999.7049  0.785
1999 Matthews RT, Klivenyi P, Mueller G, Yang L, Wermer M, Thomas CE, Beal MF. Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Experimental Neurology. 157: 120-6. PMID 10222114 DOI: 10.1006/Exnr.1999.7045  0.757
1999 Klevenyi P, Andreassen O, Ferrante RJ, Schleicher JR, Friedlander RM, Beal MF. Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport. 10: 635-8. PMID 10208603 DOI: 10.1097/00001756-199902250-00035  0.505
1999 Fiskum G, Murphy AN, Beal MF. Mitochondria in neurodegeneration: Acute ischemia and chronic neurodegenerative diseases Journal of Cerebral Blood Flow and Metabolism. 19: 351-369. PMID 10197505 DOI: 10.1097/00004647-199904000-00001  0.367
1999 Ferrante RJ, Hantraye P, Brouillet E, Beal MF. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Research. 823: 177-82. PMID 10095024 DOI: 10.1016/S0006-8993(99)01166-X  0.651
1999 Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 5: 347-50. PMID 10086395 DOI: 10.1038/6568  0.725
1999 Bogdanov MB, Ferrante RJ, Mueller G, Ramos LE, Martinou JC, Beal MF. Oxidative stress is attenuated in mice overexpressing BCL-2. Neuroscience Letters. 262: 33-6. PMID 10076866 DOI: 10.1016/S0304-3940(99)00047-6  0.569
1999 Browne SE, Ayata C, Huang PL, Moskowitz MA, Beal MF. The cerebral metabolic consequences of nitric oxide synthase deficiency: glucose utilization in endothelial and neuronal nitric oxide synthase null mice. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 19: 144-8. PMID 10027769 DOI: 10.1097/00004647-199902000-00005  0.554
1999 Ayoub IA, Lee EJ, Ogilvy CS, Beal MF, Maynard KI. Nicotinamide reduces infarction up to two hours after the onset of permanent focal cerebral ischemia in Wistar rats. Neuroscience Letters. 259: 21-4. PMID 10027546 DOI: 10.1016/S0304-3940(98)00881-7  0.315
1999 Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathology (Zurich, Switzerland). 9: 147-63. PMID 9989457 DOI: 10.1111/J.1750-3639.1999.Tb00216.X  0.589
1999 Mecocci P, Fanó G, Fulle S, MacGarvey U, Shinobu L, Polidori MC, Cherubini A, Vecchiet J, Senin U, Beal MF. Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle. Free Radical Biology & Medicine. 26: 303-8. PMID 9895220 DOI: 10.1016/S0891-5849(98)00208-1  0.769
1999 Disatnik MH, Dhawan J, Yu Y, Beal MF, Whirl MM, Franco AA, Rando TA. Evidence of oxidative stress in mdx mouse muscle: studies of the pre-necrotic state. Journal of the Neurological Sciences. 161: 77-84. PMID 9879685 DOI: 10.1016/S0022-510X(98)00258-5  0.302
1999 LEZZA A, MECOCCI P, CORMIO A, BEAL MF, CHERUBINI A, CANTATORE P, SENIN U, GADALETA M. Area-Specific Differences in OH8dG and mtDNA4977 Levels in Alzheimer Disease Patients and Aged Controls Journal of Anti-Aging Medicine. 2: 209-216. DOI: 10.1089/Rej.1.1999.2.209  0.613
1998 Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, Parker WD. Retraction. Proceedings of the National Academy of Sciences of the United States of America. 95: 12069. PMID 16578857  0.626
1998 Schulz JB, Weller M, Matthews RT, Heneka MT, Groscurth P, Martinou JC, Lommatzsch J, von Coelln R, Wüllner U, Löschmann PA, Beal MF, Dichgans J, Klockgether T. Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death and Differentiation. 5: 847-57. PMID 10203688 DOI: 10.1038/sj.cdd.4400420  0.423
1998 Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Progress in Brain Research. 116: 331-47. PMID 9932386 DOI: 10.1016/S0079-6123(08)60446-X  0.634
1998 Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. Journal of Neurochemistry. 71: 2642-4. PMID 9832167 DOI: 10.1046/J.1471-4159.1998.71062642.X  0.626
1998 Klivenyi P, Beal MF, Ferrante RJ, Andreassen OA, Wermer M, Chin MR, Bonventre JV. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. Journal of Neurochemistry. 71: 2634-7. PMID 9832165 DOI: 10.1046/J.1471-4159.1998.71062634.X  0.65
1998 Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB, Hyman BT, Beal MF. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 8145-52. PMID 9763461 DOI: 10.1523/Jneurosci.18-20-08145.1998  0.704
1998 Andreassen OA, Ferrante RJ, Beal MF, Jørgensen HA. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience. 87: 639-48. PMID 9758230 DOI: 10.1016/S0306-4522(98)00160-2  0.369
1998 Beal MF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis Annals of Neurology. 44. PMID 9749581 DOI: 10.1002/Ana.410440716  0.439
1998 Polidori MC, Frei B, Cherubini A, Nelles G, Rordorf G, Keaney JF, Schwamm L, Mecocci P, Koroshetz WJ, Beal MF. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radical Biology & Medicine. 25: 561-7. PMID 9741593 DOI: 10.1016/S0891-5849(98)00085-9  0.576
1998 Bogdanov MB, Ramos LE, Xu Z, Beal MF. Elevated 'hydroxyl radical' generation in vivo in an animal model of amyotrophic lateral sclerosis Journal of Neurochemistry. 71: 1321-1324. PMID 9721759 DOI: 10.1046/J.1471-4159.1998.71031321.X  0.383
1998 Klivenyi P, Matthews RT, Wermer M, Yang L, MacGarvey U, Becker DA, Natero R, Beal MF. Azulenyl nitrone spin traps protect against MPTP neurotoxicity. Experimental Neurology. 152: 163-6. PMID 9682023 DOI: 10.1006/Exnr.1998.6824  0.7
1998 Matthews RT, Yang L, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proceedings of the National Academy of Sciences of the United States of America. 95: 8892-7. PMID 9671775 DOI: 10.1073/Pnas.95.15.8892  0.658
1998 Browne SE, Bowling AC, Baik MJ, Gurney M, Brown RH, Beal MF. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. Journal of Neurochemistry. 71: 281-7. PMID 9648876 DOI: 10.1046/J.1471-4159.1998.71010281.X  0.67
1998 Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, Perry G. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 46: 731-5. PMID 9603784 DOI: 10.1177/002215549804600605  0.481
1998 Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Research. 783: 109-14. PMID 9479058 DOI: 10.1016/S0006-8993(97)01192-X  0.332
1998 Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease The Journal of Neuroscience. 18: 156-163. DOI: 10.1523/Jneurosci.18-01-00156.1998  0.631
1998 Klein AM, Ferrante RJ, Kowall NW, Matthews RT, McKee AC, Kaddurak-Daouk R, Beal MF. CREATINE AND CYCLOCREATINE ATTENUATE MPTP NEUROTOXICITY Journal of Neuropathology and Experimental Neurology. 57: 510. DOI: 10.1097/00005072-199805000-00183  0.353
1997 Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology. 42: 644-54. PMID 9382477 DOI: 10.1002/ana.410420416  0.481
1997 Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Journal of Neurochemistry. 69: 2064-74. PMID 9349552 DOI: 10.1046/J.1471-4159.1997.69052064.X  0.804
1997 Beal MF. New techniques for investigating mitochondrial DNA in neurodegenerative diseases Neurology. 49: 907-908. PMID 9339665 DOI: 10.1212/Wnl.49.4.907  0.348
1997 Matthews RT, Beal MF, Fallon J, Fedorchak K, Huang PL, Fishman MC, Hyman BT. MPP+ induced substantia nigra degeneration is attenuated in nNOS knockout mice. Neurobiology of Disease. 4: 114-21. PMID 9331901 DOI: 10.1006/Nbdi.1997.0141  0.427
1997 Schulz JB, Matthews RT, Klockgether T, Dichgans J, Beal MF. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Molecular and Cellular Biochemistry. 174: 193-7. PMID 9309687 DOI: 10.1023/A:1006852306789  0.542
1997 Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, Gurney ME, Beal MF. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Annals of Neurology. 42: 326-34. PMID 9307254 DOI: 10.1002/Ana.410420309  0.773
1997 Ayata C, Ayata G, Hara H, Matthews RT, Beal MF, Ferrante RJ, Endres M, Kim A, Christie RH, Waeber C, Huang PL, Hyman BT, Moskowitz MA. Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 6908-17. PMID 9278526 DOI: 10.1523/Jneurosci.17-18-06908.1997  0.377
1997 Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, Avellini L, Romano G, Senin U. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Molecular and Chemical Neuropathology / Sponsored by the International Society For Neurochemistry and the World Federation of Neurology and Research Groups On Neurochemistry and Cerebrospinal Fluid. 31: 53-64. PMID 9271005 DOI: 10.1007/Bf02815160  0.625
1997 Beal MF, Matthews RT. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Molecular Aspects of Medicine. 18: S169-79. PMID 9266519 DOI: 10.1016/S0098-2997(97)00024-1  0.318
1997 Bruijn LI, Beal MF, Becher MW, Schulz JB, Wong PC, Price DL, Cleveland DW. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proceedings of the National Academy of Sciences of the United States of America. 94: 7606-11. PMID 9207139 DOI: 10.1073/Pnas.94.14.7606  0.464
1997 Matthews RT, Ferrante RJ, Jenkins BG, Browne SE, Goetz K, Berger S, Chen IY, Beal MF. Iodoacetate produces striatal excitotoxic lesions. Journal of Neurochemistry. 69: 285-9. PMID 9202321 DOI: 10.1046/J.1471-4159.1997.69010285.X  0.532
1997 Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Annals of Neurology. 41: 646-53. PMID 9153527 DOI: 10.1002/ana.410410514  0.637
1997 Schulz JB, Panahian N, Chen YI, Beal MF, Moskowitz MA, Rosen BR, Jenkins BG. Facilitation of postischemic reperfusion with alpha-PBN: assessment using NMR and Doppler flow techniques. The American Journal of Physiology. 272: H1986-95. PMID 9139987 DOI: 10.1152/AJPHEART.1997.272.4.H1986  0.347
1997 Fallon J, Matthews RT, Hyman BT, Beal MF. MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Experimental Neurology. 144: 193-8. PMID 9126170 DOI: 10.1006/Exnr.1997.6416  0.406
1997 Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Research. 753: 157-62. PMID 9125443 DOI: 10.1016/S0006-8993(97)00008-5  0.502
1997 Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, Parker WD. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America. 94: 4526-31. PMID 9114023 DOI: 10.1073/Pnas.94.9.4526  0.716
1997 Matthews RT, Yang L, Beal MF. S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Experimental Neurology. 143: 282-6. PMID 9056390 DOI: 10.1006/Exnr.1996.6406  0.651
1997 Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Annals of Neurology. 41: 160-5. PMID 9029064 DOI: 10.1002/Ana.410410206  0.334
1997 Beal MF. Mitochondria, free radicals, and neurodegeneration. Current Opinion in Neurobiology. 6: 661-6. PMID 8937831 DOI: 10.1016/S0959-4388(96)80100-0  0.388
1997 Beal MF. Oxidative Damage in Neurodegenerative Diseases The Neuroscientist. 3: 21-27. DOI: 10.1177/107385849700300112  0.409
1997 Neil WK, Shinobu LA, Beal MF, Ferrante RJ. OXIDATIVE INJURY IN THE SPINAL CORDS OF TRANSGENIC MICE EXPRESSING MUTANT HUMAN SUPEROXIDE DISMUTASE Journal of Neuropathology and Experimental Neurology. 56: 611. DOI: 10.1097/00005072-199705000-00172  0.705
1996 Galpern WR, Matthews RT, Beal MF, Isacson O. NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease. Neuroreport. 7: 2639-42. PMID 8981438 DOI: 10.1097/00001756-199611040-00046  0.335
1996 Schulz JB, Henshaw DR, MacGarvey U, Beal MF. Involvement of oxidative stress in 3-nitropropionic acid neurotoxicity. Neurochemistry International. 29: 167-71. PMID 8837046 DOI: 10.1016/0197-0186(95)00122-0  0.475
1996 Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Medicine. 2: 1017-21. PMID 8782460 DOI: 10.1038/nm0996-1017  0.614
1996 Vécsei L, Beal MF. Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives. Biological Psychiatry. 39: 1061-3. PMID 8780845 DOI: 10.1016/0006-3223(95)00377-0  0.307
1996 Matthews RT, Beal MF. Increased 3-nitrotyrosine in brains of Apo E-deficient mice. Brain Research. 718: 181-4. PMID 8773783 DOI: 10.1016/0006-8993(95)01576-0  0.343
1996 Mecocci P, Cherubini A, Beal MF, Cecchetti R, Chionne F, Polidori MC, Romano G, Senin U. Altered mitochondrial membrane fluidity in AD brain. Neuroscience Letters. 207: 129-32. PMID 8731438 DOI: 10.1016/0304-3940(96)12509-X  0.601
1996 Kirschner PB, Jenkins BG, Schulz JB, Finkelstein SP, Matthews RT, Rosen BR, Beal MF. NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Research. 713: 178-85. PMID 8724989 DOI: 10.1016/0006-8993(95)01513-2  0.48
1996 Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature. 382: 120-1. PMID 8700201 DOI: 10.1038/382120B0  0.354
1996 Galpern WR, Frim DM, Tatter SB, Altar CA, Beal MF, Isacson O. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplantation. 5: 225-32. PMID 8689033 DOI: 10.1016/0963-6897(95)02030-6  0.367
1996 Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 71: 1043-8. PMID 8684608 DOI: 10.1016/0306-4522(95)00527-7  0.469
1996 Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH, Scott RW, Snider WD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genetics. 13: 43-7. PMID 8673102 DOI: 10.1038/Ng0596-43  0.34
1996 Schulz JB, Huang PL, Matthews RT, Passov D, Fishman MC, Beal MF. Striatal malonate lesions are attenuated in neuronal nitric oxide synthase knockout mice. Journal of Neurochemistry. 67: 430-3. PMID 8667023 DOI: 10.1046/J.1471-4159.1996.67010430.X  0.542
1996 Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 3019-25. PMID 8622131 DOI: 10.1523/Jneurosci.16-09-03019.1996  0.594
1996 Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 16: 450-61. PMID 8621749 DOI: 10.1097/00004647-199605000-00011  0.714
1996 Kowall NW, Beal MF, Brown RH, Beckman JS, Volicer L, Ferrante RJ. LOCALIZATION OF MULTIPLE HISTOCHEMICAL MARKERS OF OXIDATIVE INJURY IN PROJECTION NEURONS IN ALZHEIMER CORTEX Journal of Neuropathology and Experimental Neurology. 55: 618. DOI: 10.1097/00005072-199605000-00064  0.308
1995 Schulz JB, Matthews RT, Beal MF. Role of nitric oxide in neurodegenerative diseases. Current Opinion in Neurology. 8: 480-6. PMID 8845936 DOI: 10.1097/00019052-199512000-00016  0.442
1995 Beal MF. Neurochemistry and toxin models in Huntington's disease. Current Opinion in Neurology. 7: 542-7. PMID 7866587 DOI: 10.1097/00019052-199412000-00012  0.445
1995 Kirschner PB, Henshaw R, Weise J, Trubetskoy V, Finklestein S, Schulz JB, Beal MF. Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 15: 619-23. PMID 7790410 DOI: 10.1038/Jcbfm.1995.76  0.463
1995 Schulz JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Experimental Neurology. 132: 279-83. PMID 7789466 DOI: 10.1016/0014-4886(95)90033-0  0.509
1995 Bowling AC, Barkowski EE, McKenna-Yasek D, Sapp P, Horvitz HR, Beal MF, Brown RH. Superoxide dismutase concentration and activity in familial amyotrophic lateral sclerosis. Journal of Neurochemistry. 64: 2366-9. PMID 7722523 DOI: 10.1046/J.1471-4159.1995.64052366.X  0.493
1995 Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases Annals of Neurology. 38: 357-366. PMID 7668820 DOI: 10.1002/ana.410380304  0.314
1995 Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proceedings of the National Academy of Sciences of the United States of America. 92: 7105-9. PMID 7624378 DOI: 10.1073/Pnas.92.15.7105  0.583
1995 Beal MF, Ferrante RJ, Henshaw R, Matthews RT, Chan PH, Kowall NW, Epstein CJ, Schulz JB. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. Journal of Neurochemistry. 65: 919-22. PMID 7616254  0.451
1995 Schulz JB, Matthews RT, Jenkins BG, Brar P, Beal MF. Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 15: 948-52. PMID 7593355 DOI: 10.1038/Jcbfm.1995.120  0.474
1995 Aronin N, Chase K, Young C, Sapp E, Schwarz C, Matta N, Kornreich R, Lanwehrmeyer B, Bird E, Beal MF, Vonsattel JP, Smith T, Carraway R, Boyce FM, Young AB, et al. CAG expansion affects the expression of mutant huntingtin in the Huntington's disease brain Neuron. 15: 1193-1201. PMID 7576661 DOI: 10.1016/0896-6273(95)90106-X  0.325
1995 Schulz JB, Henshaw DR, Siwek D, Jenkins BG, Ferrante RJ, Cipolloni PB, Kowall NW, Rosen BR, Beal MF. Involvement of free radicals in excitotoxicity in vivo. Journal of Neurochemistry. 64: 2239-47. PMID 7536809 DOI: 10.1046/J.1471-4159.1995.64052239.X  0.497
1995 Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. Journal of Neurochemistry. 64: 936-9. PMID 7530297 DOI: 10.1046/J.1471-4159.1995.64020936.X  0.673
1995 Schulz JB, Beal MF. Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease. Annals of the New York Academy of Sciences. 765: 100-10; discussion 1. PMID 7486598 DOI: 10.1111/J.1749-6632.1995.Tb16565.X  0.489
1995 Bowling AC, Beal MF. Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sciences. 56: 1151-71. PMID 7475893 DOI: 10.1016/0024-3205(95)00055-B  0.596
1995 Kowall N, Ferrante R, Robert Brown JS, Beal MF. INTRACISTERNAL INFUSION OF SUPEROXIDE DISMUTASE-1 (SOD1) ANTISENSE OLIGODEOXYNUCLEOTIDE CAUSES ANTERIOR HORN CELL DEGENERATION IN VIVO Journal of Neuropathology and Experimental Neurology. 54: 417. DOI: 10.1097/00005072-199505000-00040  0.314
1994 Henshaw R, Jenkins BG, Schulz JB, Ferrante RJ, Kowall NW, Rosen BR, Beal MF. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Research. 647: 161-6. PMID 8069700 DOI: 10.1016/0006-8993(94)91412-5  0.483
1994 Beal MF, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Annals of Neurology. 36: 882-8. PMID 7998775 DOI: 10.1002/Ana.410360613  0.514
1994 Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals of Neurology. 36: 747-51. PMID 7979220 DOI: 10.1002/Ana.410360510  0.473
1994 Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. Journal of Neurochemistry. 63: 2179-84. PMID 7964738  0.494
1994 Schulz JB, Beal MF. Mitochondrial dysfunction in movement disorders. Current Opinion in Neurology. 7: 333-9. PMID 7952242  0.486
1994 Esteban J, Rosen DR, Bowling AC, Sapp P, McKenna-Yasek D, O'Regan JP, Beal MF, Horvitz HR, Brown RH. Identification of two novel mutations and a new polymorphism in the gene for Cu/Zn superoxide dismutase in patients with amyotrophic lateral sclerosis. Human Molecular Genetics. 3: 997-8. PMID 7951252 DOI: 10.1093/Hmg/3.6.997  0.468
1994 Schulz JB, Henshaw DR, Jenkins BG, Ferrante RJ, Kowall NW, Rosen BR, Beal MF. 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 14: 1024-9. PMID 7929644 DOI: 10.1038/Jcbfm.1994.134  0.477
1994 Storey E, Cipolloni PB, Ferrante RJ, Kowall NW, Beal MF. Movement disorder following excitotoxin lesions in primates. Neuroreport. 5: 1259-61. PMID 7919178  0.435
1994 Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 23: 471-6. PMID 7835898 DOI: 10.1006/Geno.1994.1525  0.302
1994 Brouillet E, Henshaw DR, Schulz JB, Beal MF. Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10. Neuroscience Letters. 177: 58-62. PMID 7824183 DOI: 10.1016/0304-3940(94)90044-2  0.649
1994 Beal MF. Energy, oxidative damage, and Alzheimer's disease: Clues to the underlying puzzle Neurobiology of Aging. 15: 171-174. PMID 7700446 DOI: 10.1016/0197-4580(94)90198-8  0.341
1994 Browne SE, Beal MF. Oxidative damage and mitochondrial dysfunction in neurodegenerative diseases. Biochemical Society Transactions. 22: 1002-6. PMID 7698395  0.498
1994 Brouillet E, Hyman BT, Jenkins BG, Henshaw DR, Schulz JB, Sodhi P, Rosen BR, Beal MF. Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Experimental Neurology. 129: 175-82. PMID 7525331 DOI: 10.1006/Exnr.1994.1159  0.614
1993 Brouillet E, Beal MF. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice. Neuroreport. 4: 387-90. PMID 8499594 DOI: 10.1097/00001756-199304000-00011  0.595
1993 Brouillet EP, Shinobu L, McGarvey U, Hochberg F, Beal MF. Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Experimental Neurology. 120: 89-94. PMID 8477830 DOI: 10.1006/exnr.1993.1042  0.774
1993 Bowling AC, Mutisya EM, Walker LC, Price DL, Cork LC, Beal MF. Age-dependent impairment of mitochondrial function in primate brain. Journal of Neurochemistry. 60: 1964-7. PMID 8473911 DOI: 10.1111/J.1471-4159.1993.Tb13430.X  0.449
1993 Nozaki K, Finklestein SP, Beal MF. Basic fibroblast growth factor protects against hypoxia-ischemia and NMDA neurotoxicity in neonatal rats. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 13: 221-8. PMID 8436614 DOI: 10.1038/Jcbfm.1993.27  0.316
1993 Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Experimental Neurology. 119: 46-71. PMID 8432351 DOI: 10.1006/exnr.1993.1006  0.508
1993 Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, Beal MF. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. Journal of Neurochemistry. 60: 356-9. PMID 8417157 DOI: 10.1111/J.1471-4159.1993.Tb05859.X  0.58
1993 Bowling AC, Schulz JB, Brown RH, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. Journal of Neurochemistry. 61: 2322-5. PMID 8245985 DOI: 10.1111/J.1471-4159.1993.Tb07478.X  0.61
1993 Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, Beal MF. Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Annals of Neurology. 34: 609-16. PMID 8215249 DOI: 10.1002/Ana.410340416  0.511
1993 Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics. 17: 171-84. PMID 8104867 DOI: 10.1006/Geno.1993.1299  0.34
1993 Srivastava R, Brouillet E, Beal MF, Storey E, Hyman BT. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: a stereological estimate of neuronal loss. Neurobiology of Aging. 14: 295-301. PMID 8103573 DOI: 10.1016/0197-4580(93)90114-Q  0.689
1993 Storey E, Beal MF. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain : a Journal of Neurology. 116: 1201-22. PMID 7693298  0.486
1993 Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 13: 4181-92. PMID 7692009  0.655
1993 Beal MF, Brouillet E, Jenkins B, Henshaw R, Rosen B, Hyman BT. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. Journal of Neurochemistry. 61: 1147-50. PMID 7689641 DOI: 10.1111/J.1471-4159.1993.Tb03633.X  0.612
1993 Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends in Neurosciences. 16: 125-31. PMID 7682343 DOI: 10.1016/0166-2236(93)90117-5  0.416
1993 Beal M, Brouillet E, Jenkins B, Ferrante R, Kowall N, Miller J, Storey E, Srivastava R, Rosen B, Hyman B. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid The Journal of Neuroscience. 13: 4181-4192. DOI: 10.1523/Jneurosci.13-10-04181.1993  0.788
1992 Vécsei L, Miller J, MacGarvey U, Beal MF. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Research Bulletin. 28: 233-8. PMID 1596743 DOI: 10.1016/0361-9230(92)90184-Y  0.689
1992 Storey E, Hyman BT, Jenkins B, Brouillet E, Miller JM, Rosen BR, Beal MF. 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. Journal of Neurochemistry. 58: 1975-8. PMID 1560246 DOI: 10.1111/J.1471-4159.1992.Tb10080.X  0.702
1992 Beal MF. Role of excitotoxicity in human neurological disease Current Opinion in Neurobiology. 2: 657-662. PMID 1422123 DOI: 10.1016/0960-9822(92)90039-D  0.319
1992 Martin JB, Beal MF. Huntington's disease and neurotoxins. Annals of the New York Academy of Sciences. 648: 169-75. PMID 1386201 DOI: 10.1111/J.1749-6632.1992.Tb24535.X  0.324
1992 Beal MF, Matson WR, Storey E, Milbury P, Ryan EA, Ogawa T, Bird ED. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. Journal of the Neurological Sciences. 108: 80-7. PMID 1385624 DOI: 10.1016/0022-510X(92)90191-M  0.56
1992 Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Annals of Neurology. 31: 119-30. PMID 1349466 DOI: 10.1002/ANA.410310202  0.322
1992 Storey E, Kowall NW, Finn SF, Mazurek MF, Beal MF. The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex. Annals of Neurology. 32: 526-34. PMID 1280937 DOI: 10.1002/Ana.410320408  0.549
1991 Finn SF, Swartz KJ, Beal MF. 2-Chloroadenosine attenuates NMDA, kainate, and quisqualate toxicity. Neuroscience Letters. 126: 191-4. PMID 1922933 DOI: 10.1016/0304-3940(91)90551-4  0.315
1991 Finn SF, Hyman BT, Storey E, Miller JM, Beal MF. Effects of aging on quinolinic acid lesions in rat striatum. Brain Research. 562: 276-80. PMID 1837750 DOI: 10.1016/0006-8993(91)90631-5  0.512
1991 Beal MF, Swartz KJ, Hyman BT, Storey E, Finn SF, Koroshetz W. Aminooxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. Journal of Neurochemistry. 57: 1068-73. PMID 1830613 DOI: 10.1111/J.1471-4159.1991.Tb08258.X  0.559
1991 Uemura Y, Kowall NW, Beal MF. Global ischemia induces NMDA receptor-mediated c-fos expression in neurons resistant to injury in gerbil hippocampus. Brain Research. 542: 343-7. PMID 1827611 DOI: 10.1016/0006-8993(91)91589-S  0.468
1991 Heyes MP, Swartz KJ, Markey SP, Beal MF. Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease. Neuroscience Letters. 122: 265-9. PMID 1827518 DOI: 10.1016/0304-3940(91)90874-S  0.33
1991 Uemura Y, Miller JM, Matson WR, Beal MF. Neurochemical analysis of focal ischemia in rats. Stroke; a Journal of Cerebral Circulation. 22: 1548-53. PMID 1720576  0.422
1991 Beal MF, Walker LC, Storey E, Segar L, Price DL, Cork LC. Neurotransmitters in neocortex of aged rhesus monkeys. Neurobiology of Aging. 12: 407-12. PMID 1685218 DOI: 10.1016/0197-4580(91)90065-R  0.48
1990 Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. Journal of Neurochemistry. 55: 1327-39. PMID 2144582 DOI: 10.1111/J.1471-4159.1990.Tb03143.X  0.335
1990 Freese A, DiFiglia M, Koroshetz WJ, Beal MF, Martin JB. Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures. Brain Research. 521: 254-64. PMID 1976413 DOI: 10.1016/0006-8993(90)91550-Z  0.304
1990 Beal MF. Somatostatin in neurodegenerative illnesses Metabolism. 39: 116-119. PMID 1976204 DOI: 10.1016/0026-0495(90)90226-3  0.384
1990 Uemura Y, Kowall NW, Beal MF. Selective sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum. Annals of Neurology. 27: 620-5. PMID 1972876 DOI: 10.1002/Ana.410270606  0.536
1990 Beal MF, MacGarvey U, Swartz KJ. Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease. Annals of Neurology. 28: 157-61. PMID 1699471 DOI: 10.1002/Ana.410280207  0.333
1990 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ. Homocysteic acid lesions in rat striatum spare somatostatin-neuropeptide Y (NADPH-diaphorase) neurons. Neuroscience Letters. 108: 36-42. PMID 1689475 DOI: 10.1016/0304-3940(90)90702-B  0.331
1989 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse (New York, N.Y.). 3: 38-47. PMID 2563916 DOI: 10.1002/Syn.890030106  0.33
1989 Clevens RA, Beal MF. Substance P-like immunoreactivity in brains with pathological features of Parkinson's and Alzheimer's diseases. Brain Research. 486: 387-90. PMID 2471578 DOI: 10.1016/0006-8993(89)90529-5  0.336
1989 Kowall NW, Beal MF. Galanin-like immunoreactivity is present in human substantia innominata and in senile plaques in Alzheimer's disease. Neuroscience Letters. 98: 118-23. PMID 2469045 DOI: 10.1016/0304-3940(89)90384-4  0.355
1988 Beal MF, Clevens RA, Mazurek MF. Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes. Synapse (New York, N.Y.). 2: 463-7. PMID 2903567 DOI: 10.1002/Syn.890020415  0.345
1988 Beal MF, Mazurek MF, Ellison DW, Swartz KJ, McGarvey U, Bird ED, Martin JB. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Annals of Neurology. 23: 562-9. PMID 2900622 DOI: 10.1002/Ana.410230606  0.335
1988 Kowall NW, Beal MF. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease. Annals of Neurology. 23: 105-14. PMID 2897822 DOI: 10.1002/Ana.410230202  0.353
1988 Beal MF, Clevens RA, Chattha GK, MacGarvey UM, Mazurek MF, Gabriel SM. Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex. Journal of Neurochemistry. 51: 1935-41. PMID 2460590 DOI: 10.1111/J.1471-4159.1988.Tb01181.X  0.377
1988 Beal MF, Swartz KJ, Finn SF, Bird ED, Martin JB. Amino acid and neuropeptide neurotransmitters in Huntington's disease cerebellum. Brain Research. 454: 393-6. PMID 2457409 DOI: 10.1016/0006-8993(88)90844-X  0.341
1988 Beal MF, Ellison DW, Mazurek MF, Swartz KJ, Malloy JR, Bird ED, Martin JB. A detailed examination of substance P in pathologically graded cases of Huntington's disease. Journal of the Neurological Sciences. 84: 51-61. PMID 2452859 DOI: 10.1016/0022-510X(88)90173-6  0.347
1988 Ellison DW, Clevens RA, Beal MF. Cortical amino acids in Brains with pathological features of Parkinson's and Alzheimer's diseases Neurochemical Pathology. 8: 53-62. DOI: 10.1007/Bf03160135  0.334
1987 Chattha GK, Beal MF. Effect of cysteamine on somatostatin and neuropeptide Y in rat striatum and cortical synaptosomes. Brain Research. 401: 359-64. PMID 3815102 DOI: 10.1016/0006-8993(87)91421-1  0.315
1987 Ellison DW, Beal MF, Martin JB. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease. Brain Research. 417: 389-92. PMID 2958109 DOI: 10.1016/0006-8993(87)90471-9  0.383
1987 Ferrante RJ, Beal MF, Kowall NW, Richardson EP, Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Research. 411: 162-6. PMID 2955849 DOI: 10.1016/0006-8993(87)90694-9  0.352
1987 Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. Journal of Neuropathology and Experimental Neurology. 46: 12-27. PMID 2947977 DOI: 10.1097/00005072-198701000-00002  0.346
1987 Beal MF, Mazurek MF, McKee MA. The regional distribution of somatostatin and neuropeptide Y in control and Alzheimer's disease striatum. Neuroscience Letters. 79: 201-6. PMID 2890123 DOI: 10.1016/0304-3940(87)90697-5  0.314
1986 Beal MF, Mazurek MF, Martin JB. Somatostatin immunoreactivity is reduced in Parkinson's disease dementia with Alzheimer's changes. Brain Research. 397: 386-8. PMID 3801878 DOI: 10.1016/0006-8993(86)90644-X  0.326
1986 Beal MF, Mazurek MF, Svendsen CN, Bird ED, Martin JB. Widespread reduction of somatostatin-like immunoreactivity in the cerebral cortex in Alzheimer's disease. Annals of Neurology. 20: 489-95. PMID 3789664 DOI: 10.1002/Ana.410200408  0.344
1986 Beal MF, Mazurek MF, Chattha GK, Svendsen CN, Bird ED, Martin JB. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Annals of Neurology. 20: 282-8. PMID 3767313 DOI: 10.1002/Ana.410200303  0.34
1986 Beal MF, Martin JB. Neuropeptides in neurological disease. Annals of Neurology. 20: 547-65. PMID 2947536 DOI: 10.1002/Ana.410200502  0.365
1986 Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB. A postmortem study of amino acid neurotransmitters in Alzheimer's disease. Annals of Neurology. 20: 616-21. PMID 2878639 DOI: 10.1002/Ana.410200510  0.333
1986 Beal MF, Benoit R, Mazurek MF, Bird ED, Martin JB. Somatostatin-28(1-12)-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Brain Research. 368: 380-3. PMID 2870772 DOI: 10.1016/0006-8993(86)90586-X  0.324
1985 Beal MF, Domesick VB, Martin JB. Effects of lesions in the amygdala and periventricular hypothalamus on striatal somatostatin-like immunoreactivity. Brain Research. 330: 309-16. PMID 3986546 DOI: 10.1016/0006-8993(85)90690-0  0.3
1985 Kowall NW, Beal MF, Ferrante RJ, Martin JB. Topography of nicotinamide adenine dinucleotide phosphate-diaphorase staining neurons in rat striatum. Neuroscience Letters. 59: 61-6. PMID 2931630 DOI: 10.1016/0304-3940(85)90215-0  0.313
1985 Beal MF, Marshall PE, Burd GD, Landis DM, Martin JB. Excitotoxin lesions do not mimic the alteration of somatostatin in Huntington's disease. Brain Research. 361: 135-45. PMID 2867808 DOI: 10.1016/0006-8993(85)91283-1  0.365
1985 Beal MF, Benoit R, Bird ED, Martin JB. Immunoreactive somatostatin-28(1-12) is increased in Huntington's disease. Neuroscience Letters. 56: 377-80. PMID 2862613 DOI: 10.1016/0304-3940(85)90272-1  0.325
1984 Beal MF, Martin JB. Effects of neuroleptic drugs on brain somatostatin-like-immunoreactivity. Neuroscience Letters. 47: 125-30. PMID 6146954 DOI: 10.1016/0304-3940(84)90417-8  0.311
1983 Beal MF, Martin JB. Effects of lesions on somatostatin-like immunoreactivity in the rat striatum. Brain Research. 266: 67-73. PMID 6133592 DOI: 10.1016/0006-8993(83)91309-4  0.33
Show low-probability matches.